Meningococcal Clinical Trials in Seoul
2 recruitingSeoul, South Korea
Showing 1–2 of 2 trials
Recruiting
Phase 2Phase 3
Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old
Meningococcal Infections
EyeGene Inc.1,123 enrolled1 locationNCT07204457
Recruiting
Phase 4
A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age
Meningitis, Meningococcal
GlaxoSmithKline50 enrolled10 locationsNCT06113198